47 related articles for article (PubMed ID: 18790640)
1. Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling.
Tong Y; Stewart KD; Thomas S; Przytulinska M; Johnson EF; Klinghofer V; Leverson J; McCall O; Soni NB; Luo Y; Lin NH; Sowin TJ; Giranda VL; Penning TD
Bioorg Med Chem Lett; 2008 Oct; 18(19):5206-8. PubMed ID: 18790640
[TBL] [Abstract][Full Text] [Related]
2. Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A.
Sarno S; Mazzorana M; Traynor R; Ruzzene M; Cozza G; Pagano MA; Meggio F; Zagotto G; Battistutta R; Pinna LA
Cell Mol Life Sci; 2012 Feb; 69(3):449-60. PubMed ID: 21720886
[TBL] [Abstract][Full Text] [Related]
3. Flexibility of the P-loop of Pim-1 kinase: observation of a novel conformation induced by interaction with an inhibitor.
Parker LJ; Watanabe H; Tsuganezawa K; Tomabechi Y; Handa N; Shirouzu M; Yuki H; Honma T; Ogawa N; Nagano T; Yokoyama S; Tanaka A
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Aug; 68(Pt 8):860-6. PubMed ID: 22869110
[TBL] [Abstract][Full Text] [Related]
4. Targeting Pim Kinases and DAPK3 to Control Hypertension.
Carlson DA; Singer MR; Sutherland C; Redondo C; Alexander LT; Hughes PF; Knapp S; Gurley SB; Sparks MA; MacDonald JA; Haystead TAJ
Cell Chem Biol; 2018 Oct; 25(10):1195-1207.e32. PubMed ID: 30033129
[TBL] [Abstract][Full Text] [Related]
5. What doesn't fit is made to fit: Pim-1 kinase adapts to the configuration of stilbene-based inhibitors.
Hochban PMM; Heyder L; Heine A; Diederich WE
Arch Pharm (Weinheim); 2024 Jun; 357(6):e2400094. PubMed ID: 38631036
[TBL] [Abstract][Full Text] [Related]
6. Virtual Screening and Design with Machine Intelligence Applied to Pim-1 Kinase Inhibitors.
Schneider P; Welin M; Svensson B; Walse B; Schneider G
Mol Inform; 2020 Sep; 39(9):e2000109. PubMed ID: 33448694
[TBL] [Abstract][Full Text] [Related]
7. Pim kinase inhibitors in cancer: medicinal chemistry insights into their activity and selectivity.
Alnabulsi S; Al-Hurani EA
Drug Discov Today; 2020 Sep; ():. PubMed ID: 32971234
[TBL] [Abstract][Full Text] [Related]
8. Access to β-Alkylated γ-Functionalized Ketones via Conjugate Additions to Arylideneisoxazol-5-ones and Mo(CO)
Macchia A; Summa FF; Monaco G; Eitzinger A; Ofial AR; Di Mola A; Massa A
ACS Omega; 2022 Mar; 7(10):8808-8818. PubMed ID: 35309475
[TBL] [Abstract][Full Text] [Related]
9. A review on PIM kinases in tumors.
Arrouchi H; Lakhlili W; Ibrahimi A
Bioinformation; 2019; 15(1):40-45. PubMed ID: 31359998
[TBL] [Abstract][Full Text] [Related]
10. PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value.
Xu J; Xiong G; Cao Z; Huang H; Wang T; You L; Zhou L; Zheng L; Hu Y; Zhang T; Zhao Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):133. PubMed ID: 27596051
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 2,1-benzisoxazole-3(1H)-ones by base-mediated photochemical N-O bond-forming cyclization of 2-azidobenzoic acids.
Dzhons DY; Budruev AV
Beilstein J Org Chem; 2016; 12():874-81. PubMed ID: 27340478
[TBL] [Abstract][Full Text] [Related]
12. Pim-1 kinase as cancer drug target: An update.
Tursynbay Y; Zhang J; Li Z; Tokay T; Zhumadilov Z; Wu D; Xie Y
Biomed Rep; 2016 Feb; 4(2):140-146. PubMed ID: 26893828
[TBL] [Abstract][Full Text] [Related]
13. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
Ciceri P; Müller S; O'Mahony A; Fedorov O; Filippakopoulos P; Hunt JP; Lasater EA; Pallares G; Picaud S; Wells C; Martin S; Wodicka LM; Shah NP; Treiber DK; Knapp S
Nat Chem Biol; 2014 Apr; 10(4):305-12. PubMed ID: 24584101
[TBL] [Abstract][Full Text] [Related]
14. Clinical and therapeutic relevance of PIM1 kinase in gastric cancer.
Yan B; Yau EX; Samanta S; Ong CW; Yong KJ; Ng LK; Bhattacharya B; Lim KH; Soong R; Yeoh KG; Deng N; Tan P; Lam Y; Salto-Tellez M;
Gastric Cancer; 2012 Apr; 15(2):188-97. PubMed ID: 21993851
[TBL] [Abstract][Full Text] [Related]
15. Pim-1 kinase inhibits pathological injury by promoting cardioprotective signaling.
Fischer KM; Cottage CT; Konstandin MH; Völkers M; Khan M; Sussman MA
J Mol Cell Cardiol; 2011 Oct; 51(4):554-8. PubMed ID: 21255581
[TBL] [Abstract][Full Text] [Related]
16. The Pim protein kinases regulate energy metabolism and cell growth.
Beharry Z; Mahajan S; Zemskova M; Lin YW; Tholanikunnel BG; Xia Z; Smith CD; Kraft AS
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):528-33. PubMed ID: 21187426
[TBL] [Abstract][Full Text] [Related]
17. Why target PIM1 for cancer diagnosis and treatment?
Magnuson NS; Wang Z; Ding G; Reeves R
Future Oncol; 2010 Sep; 6(9):1461-78. PubMed ID: 20919829
[TBL] [Abstract][Full Text] [Related]
18. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
[TBL] [Abstract][Full Text] [Related]
19. Discovery of colon tumor cell growth inhibitory agents through a combinatorial approach.
Abadi AH; Abouel-Ella DA; Lehmann J; Tinsley HN; Gary BD; Piazza GA; Abdel-Fattah MA
Eur J Med Chem; 2010 Jan; 45(1):90-7. PubMed ID: 19836860
[TBL] [Abstract][Full Text] [Related]
20. Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-kappaB pathway.
Ren K; Zhang W; Shi Y; Gong J
Pathol Oncol Res; 2010 Jun; 16(2):229-37. PubMed ID: 19821157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
